Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 3933-3940

  Holwell, S E ^a   Cooper, P A ^a   Thompson, M J ^a   Pettit, G R ^b   Lippert III, J W ^b   Martin, S W ^a   Bibby, M C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Anti tumor; Anti vascular; Combretastatin; Metastasis; Murine

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN; COMBRETASTATIN A 1 PHOSPHATE; COMBRETASTATIN A 4 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHORIC ACID ESTERS; STILBENES; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0036875993     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pettit GR, Singh SB, Niven ML, Hamel E and Schmidt JM: Isolation, structure and synthesis of combretastatins A1 and B1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50: 119-31, 1987.
2. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 45: 209-11, 1989.
3. McGown AT and Fox BW: Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anti-Cancer Drug Des 3: 249-54, 1989.
4. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA and Bansal N: Antineoplastic agents 322. Synthesis of combretastatin A4 prodrugs. Anti-Cancer Drug Des 10: 299-309, 1995.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A4, an agent that displays potent and selective toxicity towards tumour vasculature. Cancer Res 57: 1829-34, 1997.
6. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-27, 1999.
7. Stevenson JP, Gallagher M, Sun W, Algazy K, Vaughn DJ, Haller DG, Hiller K, Halloran L and O'Dwyer PJ: Phase I/Pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days. Proc Am Assoc Cancer Res 41: 54, 2000.
8. Galbraith SM, Taylor NJ, Lodge M, Tozer GM, Baddeley H, Wilson I, Prise VE and Rustin GJS: Combretastatin A4 phosphate targets vasculature in animal and human tumours. Br J Cancer 83: suppl 1, 12, 2000.
9. Pettit GG and Lippert III JW: Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. AntiCancer Drug Design 15: 203-216, 2000.
10. Chaplin DJ, Pettit GR, Parkins CS and Hill SA: Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74 suppl XXVII, S86-S88, 1996.
11. Holwell SE, Cooper PA, Grosios G, LippertIII JW, Pettit GR, Shnyder SD and Bibby MC: Combretastatin A-1 phosphate a novel tubulin binding agent with in vivo antivascular effects in experimental tumors. Anticancer Res 22: 707-712, 2002.
12. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia. Br J Cancer 77: 1-10, 1998.
13. Fogh J and Trempe G: Human Tumour Cells In Vitro. Fogh J (ed). New York, Plenum Press, 1975.
14. Dexter DL, Spremulli EN, Fligiel Z, Barbosa JA, Vogel R, vanVoorhees A and Calabresi P: Heterogeneity of cancer cells from a single human colon carcinoma. Am J Cancer 71: 949-56, 1981.
15. Double JA, Ball CR and Cowen PN: Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst 54: 271-5, 1975.
16. Geran RI, Greenberg NH and MacDonald MM: Protocols for screening chemical agents and natural products against tumours and other biological systems (Third Ed). Cancer Chemotherapy Reports 3: 1-1033, 1972.
17. Smith KA, Hill SA, Begg AC and Denekamp J: Validation of the fluorescent dye Hoechst 33342 as vascular space marker for tumours. Br J Cancer 57: 247-53, 1988.
18. Cowen SE, Bibby MC and Double JA: Characterisation of the Vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncologica 34: 357-60, 1995.
19. Chaplin DJ, Pettit GR and Hill SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-96, 1999.
20. Grosios K, Loadman PM, Swaine DJ, Pettit GR and Bibby MC: Combination chemotherapy with combretastatin A4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20: 229-33, 2000.
21. Smith KA, Begg AC and Denekamp J: Differences in chemo-sensitivity between subcutaneous and pulmonary tumours. Eur J Cancer Clin Oncol 21: 249-56, 1985.
22. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong ZY and Fan D: Modulation of the tumor-cell response to chemotherapy by the organ environment. Cancer Met Rev 13: 209-22, 1984.
23. Bibby MC: Making the most out of rodent tumour systems in cancer drug discovery. Br J Cancer 79: 1633-1640, 1999.